未知生产厂商
MV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. These include streptococcus pneumoniae and staphylococcus aureus. Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
MV130 contains different components of whole heat-inactivated gram-positive and -negative bacteria that are involved in upper and lower respiratory infections. These include streptococcus pneumoniae and staphylococcus aureus. Though studies have shown that it reduces the rate of infections in recurrent respiratory tract infections (RRTIs), the complete mechanisms are not fully understood.
Although the complete mechanisms of action are not known, MV130 is generally thought to generate Th1 immune responses. Developed by Inmunotek S.L., the compound is being assessed as a preventative therapy for the spread and course of SARS-CoV2 infection (NCT04452643), and treatment in mild infection (NCT04363814).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
